Loading provider…
Loading provider…
Hematology & Oncology Physician in Sacramento, CA
NPI: 1144479411Primary Practice Location
UNIVERSITY OF CALIFORNIA DAVIS MEDICAL CENTER
4301 X St, Sacramento, CA
Primary Employer
Lawrence J. Ellison Ambulatory Care Center
health.ucdavis.edu
HQ Phone
Get M.D., M.S. Aaron's Phone Numberphone_androidMobile
Get M.D., M.S. Aaron's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
PA State Medical License
MA State Medical License
CA State Medical License
CA State Medical License
2014 - 2026
MA State Medical License
2010 - 2015
PA State Medical License
2006 - 2010

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Icahn School Of Medicine At Mount Sinai
icahn.mssm.edu
Medical School
Until 2006
Tufts Medical Center
Fellowship • Hematology and Medical Oncology
2010 - 2013
Temple University Hospital
Residency • Internal Medicine
2007 - 2009
Internship • Internal Medicine
2006 - 2007
Wesleyan University
BA • 1997 - 2001
1997 - 2001
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 143 | 284 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 130 | 181 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 42 | 42 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 34 | 172 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 26 | 133 |
Authors: Richard Young, Caitlin Costello, Alfred Chung
Journal: J Oncol Pharm Pract
Publication Date: 2023-02-02
Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance.
Authors: Rosenberg, A S, Brunson, A, Paulus, J K, Tuscano, J, Wun, T, Keegan, T H M, Jonas, B A
Journal: Blood Cancer J
Publication Date: 2017-09-08
Lead Sponsor: GlaxoSmithKline
Intervention / Treatment: DRUG: Belantamab mafodotin
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: Isatuximab
Lead Sponsor: Kangpu Biopharmaceuticals, Ltd.
Intervention / Treatment: DRUG: KPG-818